ALAR PHARMACEUTICALS
Alar Pharmaceuticals manufactures drug products for CNS disorders and chronic diseases, opioid use disorder, chronic pain, and major depressive disorder. They also offer contract manufacturing services.
ALAR PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2016-01-01
Address:
Taichung, T'ai-wan, Taiwan
Country:
Taiwan
Website Url:
http://www.alarpharm.com
Status:
Active
Contact:
+886-4-24637115
Email Addresses:
[email protected]
Technology used in webpage:
Euro Google Maps Japanese Yen Taiwan Server Location
Similar Organizations
Bioway
Bioway is a drug development and research company.
Crescita Therapeutics
Crescita Therapeutics is a drug development company.
Crystal Genomics
Crystal Genomics is a drug research and development company.
Enceladus Pharmaceuticals
Enceladus Pharmaceuticals is a drug development company.
Ohm Oncology
Ohm Oncology is a drug development company
Polymed Biopharmaceuticals
Polymed Biopharmaceuticals is a drug research and development company.
USUN BIO
USUN BIO is a drug research and development company.
Vivozon
Vivozon is a pharmaceutical drug development company.
Stock Details
Official Site Inspections
http://www.alarpharm.com Semrush global rank: 3.75 M Semrush visits lastest month: 3.19 K
- Host name: 251.159.201.35.bc.googleusercontent.com
- IP address: 35.201.159.251
- Location:
- Latitude: 35
- Longitude: 105
- Timezone: Australia/Perth
More informations about "Alar Pharmaceuticals"
Alar Pharmaceuticals - Crunchbase Company Profile & Funding
Organization. Alar Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email …See details»
About Alar – 昱展新藥生技股份有限公司 - alarpharm.com
Skip to content. ENGLISH; 繁體中文; About Alar. Company Profile; Leadership Team; History & MilestonesSee details»
Company Profile – 昱展新藥生技股份有限公司 - alarpharm.com
Alar Pharmaceuticals Inc., established in 2016, is a new drug development company focusing on developing long-acting release drug products for CNS disorders and chronic diseases. Aiming …See details»
Alar Pharmaceuticals Inc. (Taiwan, China) - EMIS
Jul 8, 2024 Alar Pharmaceuticals Inc., a new drug development company, focusing on developing long-acting release drug products for CNS disorders and chronic diseases, which …See details»
Alar Pharmaceuticals Company Profile 2024: Valuation, Funding ...
Alar Pharmaceuticals General Information Description. Alar Pharmaceuticals Inc is a drug development company. It focuses on developing long-acting release drug products for CNS …See details»
ALAR Pharmaceuticals Inc. Overview | SignalHire Company Profile
Alar Pharmaceuticals Inc. (abbreviated as Alar), a new drug development company, was established in 2016. We focus on developing long-acting release drug products for CNS …See details»
Alar Pharmaceuticals Company Description - Stock Analysis
Dec 27, 2024 Company profile for Alar Pharmaceuticals Inc. (TPEX: 6785) with a description, list of executives, contact details and other key facts.See details»
ALAR Pharmaceuticals - Overview, News & Similar companies
Mar 8, 2021 www.alarpharm.com. Revenue $9.4 Million. Industry Manufacturing General Manufacturing . Recent News & Media. Alar Announces Significant Progress on Developing …See details»
Nextsource | Company Profile | Alar Pharmaceuticals
Explore the company profile of Alar Pharmaceuticals (alarpharm.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
Alar Pharmaceuticals Inc. - Conference Harvester
TWSE 6785 Company History 2 Sep. Alar Pharmaceuticals Inc. was founded. 2016 2019 Jul. ALA-1000 Received IND approval for SAD study from US FDA 2020 First patient injection of …See details»
ALAR Pharmaceuticals Inc. | LinkedIn
Alar Pharmaceuticals Inc. (abbreviated as Alar), a new drug development company, was established in 2016. We focus on developing long-acting release drug products for CNS …See details»
About Alar Pharmaceuticals Inc.. - CPHI Online
Established in 2016, Alar Pharmaceuticals Inc. (Alar), a new drug development company, focuses on developing long-acting release injectables (LAIs) for central nervous system (CNS) …See details»
Alar Pharmaceuticals - Craft
Oct 29, 2024 Alar Pharmaceuticals NT$469.27 m in annual revenue in FY 2023. See insights on Alar Pharmaceuticals including office locations, competitors, revenue, financials, executives, …See details»
Alar Pharmaceuticals, Inc. (昱展新药生技股份有限公司) - 药物管线_ …
了解Alar Pharmaceuticals, Inc. (昱展新药生技股份有限公司)公司的药物管线，治疗领域，技术平台，以及它的1项临床试, 1篇新闻，疾病领域:神经系统疾病，内分泌与代谢疾病，技术平台: …See details»
2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of …
Oct 28, 2021 Alar Pharmaceuticals Inc. (abbreviated as Alar Pharm), a new drug development company focused on long-acting release drug products, has announced that it concluded its …See details»
ALAR PHARMACEUTICALS INC. - BIO Asia–Taiwan
Alar Pharm, a new drug development company, focuses on developing long-acting release injectables (LAIs) for treating CNS disorders & chronic diseases, including opioid use disorder, …See details»
2022/01/13 Alar Announces Significant Progress on Developing …
Jan 12, 2022 CONTACT: IR information: [email protected]; +886-4-2463-7115. You Might Also Like. 2024/10/01 ALA-3000 has received notice of allowance from Taiwan Intellectual …See details»
Alar Pharmaceuticals Inc. (6785.TWO) - Yahoo Finance
Find the latest Alar Pharmaceuticals Inc. (6785.TWO) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Breaking the Cycle of Opioid Addiction: Alar Presents ... - 台湾新闻
Mar 10, 2021 ALA-1000 is the first, three-month slow-release Buprenorphine injection. Initial results show a low initial burst without dose dumping effect, good safety, and tolerability.See details»
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents ...
Mar 10, 2021 CONTACT: IR information: [email protected]; +886-4-2463-7115 You Might Also Like 2022/05/12 ALA-1000 Received notice of patent allowance from Director de …See details»